

ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: **Stock**

Company	2023/06/05 17:41:21
	Price
	137.45
	USD
Difference	 0.42%(0.58)



Contact Details

ABBVIE INC. Tel: +1-847-932-7900
 -- Fax: +
 1 North Waukegan Road Web: <http://www.abbvie.com>
 60064-6400 North Chicago E-mail: -

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	28,463,000,000		27,928,000,000		24,173,000,000	
Common stock capital		18,000,000		18,000,000		18,000,000
Fixed assets	110,342,000,000		118,601,000,000		126,392,000,000	
Equity capital of a company		17,287,000,000		15,436,000,000		13,097,000,000
Cash and cash equivalents	9,201,000,000		9,746,000,000		8,449,000,000	
Accrued liabilities		1,638,000,000		3,153,000,000		3,413,000,000
Other assets	-		-		-	
Current liabilities		29,538,000,000		35,194,000,000		28,661,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		91,980,000,000		95,899,000,000		108,807,000,000
Different income		-		-		-
Other liabilities		21,761,000,000		18,865,000,000		17,682,000,000
Total assets	138,805,000,000	138,805,000,000	146,529,000,000	146,529,000,000	150,565,000,000	150,565,000,000

Balance notes

	2022	2021	2020
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	50,000	50,000	47,000
Equity ratio	12.48%	10.55%	8.71%
Debt-equity ratio	701.41%	847.55%	1,047.77%

Others

	2022	2021	2020
Tax Expense Rate	12.11%	11.09%	-36.02%

ABBVIE INC.

ISIN: US00287Y1091

WKN: 00287Y109

Asset Class: **Stock**

Income statement

	2022	2021	2020
Turnover	58,054,000,000	56,197,000,000	45,804,000,000
Net income	11,782,000,000	11,468,000,000	4,556,000,000
EBIT	14,533,027,800	14,311,830,600	5,337,544,200
Operating income before taxes	13,477,000,000	12,989,000,000	3,398,000,000
Cash Flow	24,943,000,000	22,777,000,000	17,588,000,000
Net interest income	-2,160,000,000	-2,410,000,000	-2,345,000,000
Research and development expenses	6,487,000,000	6,980,000,000	6,173,000,000
Income taxes	1,632,000,000	1,440,000,000	-1,224,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,079,108	1,044,590	905,750

Board of Directors

Members of Management Board

Robert Alpern	Member of Board of Directors
Brett Hart	Member of Board of Directors
Edward Rapp	Member of Board of Directors
Frederick Waddell	Member of Board of Directors
Glenn Tilton	Member of Board of Directors
Melody Meyer	Member of Board of Directors
Rebecca Roberts	Member of Board of Directors
Robert Michael	Member of Board of Directors
Roxanne Austin	Member of Board of Directors
Thomas Freyman	Member of Board of Directors
William Burnside	Member of Board of Directors
Richard A. Gonzalez	Chairman of Managing Board
Azita Saleki-Gerhardt	Member of Executive Committee
Carrie Strom	Member of Executive Committee
Henry O. Gosebruch	Member of Executive Committee
Jeffrey R. Stewart	Member of Executive Committee
Laura J. Schumacher	Member of Executive Committee
Perry C. Siatis	Member of Executive Committee
Rae L. Livingston	Member of Executive Committee
Robert A. Michael	Member of Executive Committee
Scott T. Reents	Member of Executive Committee
Timothy J. Richmond	Member of Executive Committee